Lexaria Bioscience Corp - SIC # 2833 - MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS

Ticker Exchange SIC # Website Latest Ticker
LEXX Nasdaq 2833 https://www.lexariabioscience.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Lexaria Bioscience Corp

Is Lexaria Bioscience (NASDAQ:LEXX) In A Good Position To Deliver On Growth Plans? - Mar 7th, 2023 10:54 am
Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels - Mar 2nd, 2023 1:45 pm
Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4 - Feb 21st, 2023 2:00 pm
Lexaria Bioscience: Charting a Path to Commercial Success - Jan 31st, 2023 1:30 pm
Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor - Jan 23rd, 2023 1:45 pm
LEXX: DehydraTECH: Developing Diabetes and Dementia - Jan 17th, 2023 1:33 pm
Lexaria Releases Annual Letter from the CEO - Jan 13th, 2023 9:05 pm
Lexaria Receives First Granted Patent in Canada - Dec 29th, 2022 2:00 pm
Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels - Dec 21st, 2022 2:00 pm
Lexaria’s Human Oral Nicotine Study Begins Dosing - Dec 20th, 2022 5:35 pm
Lexaria Bioscience Full Year 2022 Earnings: Misses Expectations - Nov 30th, 2022 10:24 am
Lexaria’s DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program - Nov 29th, 2022 1:50 pm
Lexaria's DehydraTECH-CBD Enhances Performance Compared to Epidiolex in Seizure Study Program - Nov 29th, 2022 1:31 pm
Lexaria Bioscience Turns Focus to Dementia and Diabetes with New Studies - Nov 21st, 2022 2:19 pm
Lexaria Examining Potential Therapeutic Use of DehydraTECH-CBD in Dementia - Nov 10th, 2022 2:20 pm
Lexaria Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes - Nov 8th, 2022 2:10 pm
Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study - Nov 1st, 2022 1:25 pm
LEXX: DehydraTECH CBD HYPER-H21-4 Results - Oct 31st, 2022 9:26 am
Lexaria's Human Clinical Hypertension Study a Success - Oct 27th, 2022 12:45 pm
Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields 'Remarkable' Results - Sep 20th, 2022 12:30 pm